(2 November, 2020, Shanghai) 29 October, 2020, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, announced results for the nine months ended September 30, 2020 ("the Reporting Period"). 

During the Reporting Period, Fosun Pharma realized operating revenue of RMB 22,103 million, and the net profit attributable to shareholders of the listed companies amounted to RMB 2,479 million, representing an increase of 20.12% year-on-year basis; the net profit attributable to shareholders of the listed companies after deducting extraordinary gain or loss amounted to RMB 2,060 million, representing an increase of 19.57% year-on-year basis.
Enhanced Investment on 4+3 R&D Platform and Entered Intensive Harvest Period of Innovative Drugs
Fosun Pharma continues to focus on innovation and internationalization, striving to develop strategic products and optimize its pharmaceutical R&D system that integrates generic and innovative drugs, and further enhances the development of ‘4+3’ R&D platforms (Four platforms: biopharmaceutical drugs, small molecular innovative drugs, high-value generic drugs, and new technological therapy; Three systems: in-house research and development, license introduction, and incubation). During the Reporting Period, Fosun Pharma R&D expense amounted to RMB 1,878 million, representing an increase of 45.55% compared to the same period last year. 

Intensive harvest period for Fosun Pharma’s innovative R&D has come. For biologic products, HLX02 (trastuzumab for injection,汉曲优^®; EU trade name: Zercepac ^®) obtained marketing approval in the European Union and China in July and August, respectively; the new drug application of HLX04 (recombinant humanized anti-VEGF monoclonal antibody injection) has been accepted by the National Medical Products Administration (NMPA) for the treatment of metastatic colorectal cancer and advanced, metastatic or recurrent non-small cell lung cancer. The phase III clinical trial of botulinum toxin RT002 in the treatment of moderate and severe glabellar (frown) lines and cervical dystonia was approved by the National Medical Products Administration (NMPA). As for small molecules, CDK4/6 inhibitor FCN-437c has launched phase II clinical trial in China to study its effect on the indication of advanced breast cancer for ER+ and HER2-. The phase Ib clinical trial of ORIN1001 for idiopathic pulmonary fibrosis has been approved by the U.S. Food and Drug Administration (FDA). The phase III clinical trial of Avatrombopag Maleate Tablet for the adult patients with Chronic Immune Thrombocytopenia (ITP), was approved by the National Medical Products Administration (NMPA), and the Avatrombopag Maleate Tablet (苏可欣^®) was approved to be launched in April for selective thrombocytopenia treatment of adult patients with chronic liver disease undergoing diagnostic procedures or surgery.

At the same time, Fosun Pharma optimized its pharmaceutical R&D system that integrates generic and innovative drugs and actively conducted the "consistency evaluation" of generic drugs. In the third round of central purchasing list announced in August 2020, Fosun Pharma won the bid for five products, namely, pitavastatin calcium tablets, febuxostat tablets, quetiapine fumarate tablets, memantine hydrochloride tablets and ethambutol hydrochloride tablets.

Internationalization Strategy to Strengthen Global Presence
While increasing investment in innovative R&D, Fosun Pharma continues its internationalization strategy to strengthen global presence. The application for separate listing of Gland Pharma, the subsidiary of Fosun Pharma, has been approved by the China Securities Regulatory Commission and the Hong Kong Stock Exchange, and received the in-principle approval for the listing from National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE).

In terms of international collaboration, through the mature marketing network and upstream and downstream customer resources established by Tridem Pharma in the English-speaking and French-speaking regions of sub-Saharan Africa, Fosun Pharma further consolidated its competitiveness in Africa and improved the Group's international pharmaceutical marketing and sales platform; at the same time, Fosun Pharma set up marketing and sales platforms in the United States and Europe to promote in-depth collaboration with multinational pharmaceutical companies and expand the scale of pharmaceutical sales in the international market. In addition, Fosun Pharma is actively looking for excellent license-out partners around the world, Henlius signed a license agreement with Accord for the development and commercialization of HLX02 for trastuzumab injections in the United States and Canada, and signed a license agreement with ESSEX and granted an exclusive license to regulatory develop, manufacture, and commercialize HLX04 in human ophthalmic therapeutic use globally.

Practice Social Responsibility and Contribute in Preventing and Controlling the Pandemic
In the first three quarters of 2020 with the challenge of the COVID-19 pandemic, as a leading medical and healthcare group in China, Fosun Pharma responded quickly to the COVID-19 and actively practiced social responsibilities by leveraging on its own products and resources, and global resources.

Fosun Pharma, together with global member enterprises, took the initiative to support the material supply in response to the pandemic prevention and control, among which the self-developed 2019-nCoV nucleic acid detection kit (RT-PCR) passed the emergency examination and obtained the approval from the National Medical Products Administration (NMPA). At the same time, Fosun Pharma undertook to manufacture negative pressure ambulance, further expanded the manufacturing capacity of ventilator to ensure the global supply of ventilator, ensured the supply of mobile CT to reduce the risk of cross-infection in multi-departments caused by patient transfer. 

In addition, Fosun Pharma actively collaborated with BioNTech to develop mRNA vaccine. Phase I clinical trial of mRNA COVID-19 vaccine BNT162b1 started in China in July 2010. As of September 2020, all 144 participants had received two vaccinations at an interval of 21 days. Henlius’s COVID-19 neutralizing antibody HLX70 received Investigation New Drug (“IND”) approval by the FDA, making Henlius became the first Chinese pharmaceutical company to independently submit the COVID-19 neutralization antibody clinical trial application to the FDA and receive approval. Fosun Pharma will continue to work with global member enterprises and project partners to contribute more to the fight against the pandemic.

Yifang Wu, Chairman and CEO of Fosun Pharma stated, following the 4 IN (INnovation, INternationalization, INtegration and INtelligentization) strategy, Fosun Pharma will adhere to the development model of “innovation transformation, integrated operation and steady growth”, to improve products quality, branding, and innovation, integration and internationalization capabilities to address unmet medical needs.